Galectin-1 is a 14.5-kDa β-galactoside-binding protein that belongs to a 15-member protein family expressed by many different cell types. It exerts major roles in the immune system [1,2] and is involved in the progression of various cancer types [3], including melanomas and gliomas [4]. Galectin-1 displays intracellular (i.e., protein-protein interactions) and extracellular (i.e., protein-oligosaccharide interactions) functions [5]; it displays marked pro-angiogenic [6] and pro-migratory effects in gliomas and melanomas and confers these two tumor types with significant levels of resistance to chemotherapy and radiotherapy [4]. Galectin-1 also aids melanoma [2] and glioma [4] cells in escaping attacks from the immune system, though great hopes have been placed in various types of immunotherapy (including vaccinotherapy) for combating melanomas and gliomas that are associated with dismal prognoses because of their marked intrinsic resistance to proapoptotic stimuli, such as conventional chemotherapy and radiotherapy [4].